To ensure the clinical applicability and safety of CD155 CAR-T therapy, we conducted a thorough evaluation of CD155 expression in various hematopoietic and nonhematopoietic normal human tissues to assess potential on-target, off-tumor effects. This evidence concerns the gene PVR and neoplasm.